Key result
Long-term psychotropic treatment in youths, particularly second-generation antipsychotics, is linked to notable cardiometabolic risks.
Why the study?
The cardiac and metabolic effects of long-term treatment with psychotropic medications in children and adolescents require evaluation.
Does long-term treatment with psychotropics increase cardiac and metabolic risks in children and adolescents?
Does long-term treatment with psychotropics increase cardiac and metabolic risks in children and adolescents?
Long-term psychotropic medication in children and adolescents is associated with notable cardiac and metabolic risks, particularly with second-generation antipsychotics, requiring careful monitoring.
Answers are grounded in this paper and cite their sources.
May support monitoring for cardiac and metabolic risks in youths on long-term psychotropics; leaves open causality and optimal strategies.
Long-term psychotropic medication in youths is linked to notable cardiac and metabolic risks, particularly with second-generation antipsychotics, necessitating careful monitoring and management strategies.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. Long-term psychotropic medication in youths, particularly second-generation antipsychotics, is associated with notable cardiac and metabolic risks.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: